
The combined entity after the merger of Pfizer#39;s off-patent business and Mylan would become the largest generic drug maker globally, and may set the pace for the consolidation of an industry facing pricing pressure amidst competition and channel consolidation in US market.
from Moneycontrol Business News https://ift.tt/2Yda5kf
Comments
Post a Comment